GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » EV-to-Revenue

China Biotech Services Holdings (HKSE:08037) EV-to-Revenue : 1.72 (As of Jun. 06, 2024)


View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, China Biotech Services Holdings's enterprise value is HK$365.4 Mil. China Biotech Services Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$212.0 Mil. Therefore, China Biotech Services Holdings's EV-to-Revenue for today is 1.72.

The historical rank and industry rank for China Biotech Services Holdings's EV-to-Revenue or its related term are showing as below:

HKSE:08037' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.17   Med: 2.2   Max: 28.02
Current: 1.72

During the past 13 years, the highest EV-to-Revenue of China Biotech Services Holdings was 28.02. The lowest was -0.17. And the median was 2.20.

HKSE:08037's EV-to-Revenue is ranked better than
70.91% of 220 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.085 vs HKSE:08037: 1.72

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), China Biotech Services Holdings's stock price is HK$0.35. China Biotech Services Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.22. Therefore, China Biotech Services Holdings's PS Ratio for today is 1.58.


China Biotech Services Holdings EV-to-Revenue Historical Data

The historical data trend for China Biotech Services Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings EV-to-Revenue Chart

China Biotech Services Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.29 1.75 2.11 0.71 3.76

China Biotech Services Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.61 0.56 0.81 3.76

Competitive Comparison of China Biotech Services Holdings's EV-to-Revenue

For the Diagnostics & Research subindustry, China Biotech Services Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biotech Services Holdings's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's EV-to-Revenue falls into.



China Biotech Services Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

China Biotech Services Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=365.440/211.985
=1.72

China Biotech Services Holdings's current Enterprise Value is HK$365.4 Mil.
China Biotech Services Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$212.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Biotech Services Holdings  (HKSE:08037) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

China Biotech Services Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.35/0.221
=1.58

China Biotech Services Holdings's share price for today is HK$0.35.
China Biotech Services Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.22.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Biotech Services Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Biotech Services Holdings (HKSE:08037) Business Description

Traded in Other Exchanges
N/A
Address
255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.
Executives
Liu Xiaolin 2101 Beneficial owner
Genius Earn Limited 2201 Interest of corporation controlled by you
Genius Lead Limited 2101 Beneficial owner
Guoyuan International Holdings Limited 2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd. 2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited 2101 Beneficial owner
Richlane Ventures Limited 2101 Beneficial owner
Ko Chun Shun, Johnson 2201 Interest of corporation controlled by you

China Biotech Services Holdings (HKSE:08037) Headlines

No Headlines